Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

775 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Bernocchi O, Sirico M, Corona SP, Strina C, Milani M, Cappelletti MR, Ferrero G, Ziglioli N, Cervoni V, Macchiavelli A, Roviello G, Generali D. Bernocchi O, et al. Among authors: milani m. Pharmaceuticals (Basel). 2021 Feb 16;14(2):159. doi: 10.3390/ph14020159. Pharmaceuticals (Basel). 2021. PMID: 33669326 Free PMC article.
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A. Bottini A, et al. Among authors: milani m. J Clin Oncol. 2006 Aug 1;24(22):3623-8. doi: 10.1200/JCO.2005.04.5773. J Clin Oncol. 2006. PMID: 16877730 Free article. Clinical Trial.
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A. Generali D, et al. Among authors: milani m. Bone. 2007 Jan;40(1):182-8. doi: 10.1016/j.bone.2006.06.023. Epub 2006 Aug 24. Bone. 2007. PMID: 16935041
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, Bottini A, Berruti A, Generali D. Allevi G, et al. Among authors: milani m. Br J Cancer. 2013 Apr 30;108(8):1587-92. doi: 10.1038/bjc.2013.151. Epub 2013 Apr 11. Br J Cancer. 2013. PMID: 23579222 Free PMC article. Clinical Trial.
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.
Koukourakis MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, Ferrozzi F, Harris AL, Generali D. Koukourakis MI, et al. Among authors: milani m. Br J Cancer. 2014 Apr 29;110(9):2209-16. doi: 10.1038/bjc.2014.196. Epub 2014 Apr 10. Br J Cancer. 2014. PMID: 24722179 Free PMC article.
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, Petronini PG, Fox SB, Harris AL, Martinotti M, Berruti A, Bottini A, Reynolds AR, Generali D. Bazzola L, et al. Among authors: milani m. Br J Cancer. 2015 Jan 6;112(1):52-60. doi: 10.1038/bjc.2014.563. Epub 2014 Dec 2. Br J Cancer. 2015. PMID: 25461806 Free PMC article.
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of the European Blood and Marrow Transplantation Society (EBMT). Ravelli A, et al. Among authors: milani m. Expert Rev Anticancer Ther. 2015 Jun;15(6):689-702. doi: 10.1586/14737140.2015.1042864. Epub 2015 Apr 30. Expert Rev Anticancer Ther. 2015. PMID: 25927868 Review.
Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A. Generali D, et al. Among authors: milani m. J Natl Cancer Inst Monogr. 2015 May;2015(51):32-5. doi: 10.1093/jncimonographs/lgv019. J Natl Cancer Inst Monogr. 2015. PMID: 26063883
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, Bottini A, Harris AL, Fox SB. Generali D, et al. Among authors: milani m. J Natl Cancer Inst Monogr. 2015 May;2015(51):64-6. doi: 10.1093/jncimonographs/lgv018. J Natl Cancer Inst Monogr. 2015. PMID: 26063890 Clinical Trial.
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT). Ravelli A, et al. Among authors: milani m. Tumour Biol. 2015 Sep;36(9):6653-65. doi: 10.1007/s13277-015-3944-7. Epub 2015 Aug 26. Tumour Biol. 2015. PMID: 26307395 Review.
775 results